Alland Leila 4

What Happened
Leila Alland, a director of Abeona Therapeutics, sold 11,000 common shares in an open-market transaction on June 30, 2026. The filing reports a weighted-average price of $5.92 per share for total proceeds of approximately $65,087. This was a sale (S), which is often a routine liquidity transaction rather than a direct signal about company prospects.

Key Details

• Transaction date: 2026-06-30
• Filing date: 2026-07-02 (Form 4 accession 0001493152-26-031906) — appears to be filed within the normal reporting window.
• Transaction type/code: Sale (S), open-market or private sale.
• Shares sold: 11,000
• Price: reported weighted average $5.92; actual trades ranged from $5.915 to $5.9334 per share (see footnote).
• Proceeds: ~$65,087.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: F1 states the $5.92 is a weighted average and that the shares were sold in multiple transactions at prices between $5.915 and $5.9334; the reporting person will provide a breakdown on request.

Context
Sales by directors can be routine (for diversification, taxes, personal needs, etc.) and do not necessarily indicate a change in their view of the company. Purchases tend to be more informative about insider sentiment; this single modest sale (~$65k) should be viewed in that context.